Health
Expiring Pfizer Covid Drug Doses to Cost Europe $2.2 Billion
- Use of Paxlovid has waned as pandemic concerns dissipate
- Reduced sales of the treatment sparked sales outlook cut
The outdated supply includes $1.1 billion worth of doses that had already expired as of November.
Photographer: Joe Raedle/Getty ImagesThis article is for subscribers only.
Stockpiles of Pfizer Inc.’s Paxlovid in Europe and the UK worth $2.2 billion are set to expire by the end of next month as demand for the Covid-19 treatment plummets.
The outdated supply includes $1.1 billion worth of doses that had already expired as of November, according to the London-based analytics firm Airfinity Ltd. The UK has seen the biggest chunk go to waste with an estimated 1 million past-date courses at a cost of some $700 million, Airfinity said in a report.